GEN reports on ocular therapeutics targeting the retina

Genetic Engineering & Biotechnology News cover image. GEN is published 21 times per year. Credit: ©2012, Mary Ann Liebert, Inc., publishers

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, there is a critical need for new remedies, according to a recent issue of GEN.

"As increasing numbers of baby-boomers continue to grow older, many will have to deal with eye diseases such as age-related macular degeneration," said John Sterling, Editor-in-Chief of GEN. "Some estimates put the current AMD and diabetic retinopathy drug segment of the market at $3 billion, and this is expected to increase to about $5 billion in two years."

Standard therapy has been Genentech's VEGF inhibitors Lucentis and the off-label use of Avastin®. Regeneron, in collaboration with Bayer HealthCare, is challenging these drugs with a similar VEGF inhibitor, Eyela. The FDA approved the drug last November for wet AMD.

In another approach, Acucela is in Phase II trials using visual cycle modulators to lighten the metabolic load on the retina by reducing the activity of the rod visual system. This protects the retina from light damage, improves retinal vasculature, and reduces the accumulation of A2E and other retinal-related toxic by-products.

GlaxoSmithKline has two drugs in Phase II trials for ocular therapy: darapladib, an oral Lp-PLA2 inhibitor for diabetic macular edema, and Votrient®, a multi-kinase angiogenesis inhibitor in eye drop form for AMD. Early-stage work also is under way for neovascular AMD, dry AMD, diabetic retinopathy, diabetic macula edema, uveitis, and , as well as for technologies for drug delivery.

Related Stories

FDA approves drug to treat diabetic macular edema

date Aug 13, 2012

The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Recommended for you

Closing the Australian eye health gap may be in sight

date 18 hours ago

Three years after the launch of the roadmap to close the gap for vision, progress has been made but "much remains to be done", according to the authors of a Perspective published online today by the Medical Jo ...

Pioneering gene therapy takes aim at inherited blindness

date Jun 29, 2015

Canada's first human gene therapy trial for eyes—the replacement of a faulty gene with a healthy one—is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people ...

Iris research focuses on blood vessel patterns

date Jun 29, 2015

The structure of the microvasculature or blood vessels in the iris could play an important role in people's contraction of eye maladies like glaucoma and cataract, according to a WA-led study.

New nanotechnology drug to control blindness

date Jun 25, 2015

The Mexican company "Medical and Surgical Center for Retina" has created a way to deliver drugs in order to avoid risks and painful treatments in people with secondary blindness due to chronic degenerative ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.